Mizuho Markets Americas LLC Trims Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Mizuho Markets Americas LLC reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 375,446 shares of the biopharmaceutical company's stock after selling 62,660 shares during the quarter. Mizuho Markets Americas LLC owned approximately 0.30% of Halozyme Therapeutics worth $21,491,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of HALO. Janney Montgomery Scott LLC raised its holdings in Halozyme Therapeutics by 28.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 16,454 shares of the biopharmaceutical company's stock worth $669,000 after purchasing an additional 3,666 shares during the period. Swiss National Bank raised its holdings in Halozyme Therapeutics by 0.3% in the 1st quarter. Swiss National Bank now owns 260,900 shares of the biopharmaceutical company's stock worth $10,613,000 after purchasing an additional 900 shares during the period. US Bancorp DE raised its holdings in Halozyme Therapeutics by 64.6% in the 1st quarter. US Bancorp DE now owns 13,912 shares of the biopharmaceutical company's stock worth $566,000 after purchasing an additional 5,458 shares during the period. ProShare Advisors LLC raised its holdings in Halozyme Therapeutics by 4.9% during the first quarter. ProShare Advisors LLC now owns 38,662 shares of the biopharmaceutical company's stock valued at $1,573,000 after acquiring an additional 1,794 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its position in shares of Halozyme Therapeutics by 9.2% in the first quarter. State Board of Administration of Florida Retirement System now owns 41,550 shares of the biopharmaceutical company's stock valued at $1,587,000 after acquiring an additional 3,500 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Trading Down 15.4 %

NASDAQ:HALO traded down $8.31 during midday trading on Friday, hitting $45.65. 7,231,432 shares of the company traded hands, compared to its average volume of 1,323,263. The firm's fifty day moving average is $56.04 and its 200-day moving average is $53.27. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53. The firm has a market capitalization of $5.81 billion, a P/E ratio of 15.12, a P/E/G ratio of 0.54 and a beta of 1.29. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $61.75, for a total value of $617,500.00. Following the sale, the senior vice president now owns 168,176 shares in the company, valued at $10,384,868. This trade represents a 5.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 70,000 shares of company stock worth $4,042,500. Company insiders own 2.40% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on HALO. Cowen reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Benchmark reiterated a "buy" rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and upped their target price for the stock from $52.00 to $57.00 in a research report on Thursday, September 19th. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lifted their price target for the company from $58.00 to $62.00 in a report on Monday, October 7th. Finally, HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $65.00 to $68.00 and gave the company a "buy" rating in a report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.